Breast cancer patients have been given fresh hope after a new vaccine showed "promise" in treating an aggressive form of the ...

Compelling 24.1-month median follow-up data presented at SITC 2024 showed that all patients treated with TG4050 after completion of an adjuvant ...

Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...

Transgene and NEC will present promising new data from the ongoing randomized Phase I trial of the neoantigen individualized therapeutic cancer vaccine, TG4050 at SITC 2024 on November 9, 2024 (see ...

Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced new findings related to its ...

GRANITE vs. control in all treated population (HR=0.73 [90% CI, 0.44, 1.21]) -- -- 50% relative risk reduction of progression ...

While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...

Moderna, Inc. MRNA reported earnings of 3 cents per share in the third quarter of 2024. The Zacks Consensus Estimate was a ...

At Circio, we are developing a protein-based polyvalent KRAS neoantigen vaccine that can induce robust KRAS-specific T-cell responses in the clinic as an off-the-shelf therapeutic cancer vaccine.” ...

In the final episode, experts at UCSD and La Jolla Institute discuss current clinical trials of a cancer vaccine and future directions for neoantigen vaccines. Custom-made Cancer Therapy ...